StandardX has raised £10m in seed funding to build a UK isotope-refining platform intended to supply radioactive materials used in cancer treatment and, potentially, future fusion-energy systems.
The London deep-tech business was founded in 2025 by nuclear engineers Richard Pearson and Ross Allen. Its first financing round was led by Vsquared Ventures and East X Ventures, with participation from firstminute Capital, the UK Innovation and Science Seed Fund, Brevan Howard Macro Venture, and Geometry.
StandardX is developing a compact particle accelerator designed to produce multiple isotopes from a standardised platform rather than relying on separate equipment and geographically concentrated production facilities for different materials.
Pearson said: “Isotopes underpin the next era of innovation across several key sectors, but all share the same constraints around supply.”
Medical isotopes are used in cancer diagnosis, targeted radiotherapy, and other specialist treatments. Their supply chains can be difficult because many products have short half-lives, require specialised production facilities, and are generated by a limited number of reactors or accelerators.
StandardX argues that those constraints have become severe enough to affect clinical development. It says shortages of some materials required for targeted alpha therapies have contributed to delays in trials in the UK and Europe.
The company intends to provide its first isotopes to a medical research partner in 2027 and is targeting industrial-scale production by 2029. Its longer-term model is based on placing more flexible production capacity closer to centres of demand.
The platform is also being developed with fusion energy in mind. Tritium, an isotope of hydrogen, is one of the fuels expected to be required by several approaches to commercial fusion. Global stocks are limited, while a future fleet of reactors could create substantially larger demand if fusion plants reach commercial deployment.
StandardX says it has already entered supply agreements with fusion developers, although it has not identified the companies involved. The strategy gives the business a dual market: near-term demand from medicine and a potentially much larger but less certain opportunity in fusion.
The structure could reduce some of the commercial risk common to deep technology. Businesses tied entirely to an emerging industry can face long periods before customers are ready to buy at scale. A platform capable of serving established medical requirements while developing capability relevant to fusion could generate demand independently of the timetable for commercial reactors.
Building isotope production in the UK also connects with wider concerns around strategic supply chains. Pharmaceuticals, semiconductors, energy systems, defence, and advanced manufacturing have all prompted governments and companies to reassess dependence on highly concentrated overseas production.
Nuclear materials add further complexity because production, handling, transport, security, waste, and licensing are tightly regulated. Scaling the technology will therefore require StandardX to develop industrial capability alongside scientific performance and regulatory compliance.
The financing remains early-stage capital rather than proof that the refinery model can operate economically at full commercial scale. The accelerator approach still has to demonstrate reliable output, quality, uptime, and unit economics as production expands.
The £10m round gives StandardX funding to move that work forward. Its first commercial test will come in medical isotopes, where existing supply constraints provide a clearer near-term market than the longer timetable attached to commercial fusion.
You must be logged in to post a comment.